You just read:

SCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)

News provided by

SCYNEXIS, Inc.

May 01, 2019, 08:30 ET